首页> Blood advances> PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

导出 LinkOut

翻译打印收藏纠错

第一作者： Alberto J,Arribas

第一单位： Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland.;Swiss Institute of Bioinformatics, Lausanne, Switzerland.

作者： Alberto J,Arribas ^[1] ; Sara,Napoli ^[2] ; Eugenio,Gaudio ^[2] ; Charles,Herbaux ^[3] ; Eleonora,Cannas ^[2] ; Chiara,Tarantelli ^[2] ; Roberta,Bordone-Pittau ^[4] ; Luciano,Cascione ^[1] ; Nicolas,Munz ^[2] ; Luca,Aresu ^[5] ; Jacopo,Sgrignani ^[6] ; Andrea,Rinaldi ^[2] ; Ivo,Kwee ^[1] ; Davide,Rossi ^[7] ; Andrea,Cavalli ^[8] ; Emanuele,Zucca ^[7] ; Georg,Stussi ^[4] ; Anastasios,Stathis ^[9] ; Callum,Sloss ^[10] ; Matthew S,Davids ^[3] ; Francesco,Bertoni ^[2]

作者单位： Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland.;Swiss Institute of Bioinformatics, Lausanne, Switzerland. ^[1] Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland. ^[2] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. ^[3] Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. ^[4] Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland.;Department of Veterinary Science, University of Turin, Turin, Italy. ^[5] Institute of Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland. ^[6] Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland.;Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. ^[7] Swiss Institute of Bioinformatics, Lausanne, Switzerland.;Institute of Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland. ^[8] Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland. ^[9] Translational Sciences, Immunogen Inc, Waltham, MA. ^[10]

医学主题词人类(Humans);抗药性, 肿瘤(Drug Resistance, Neoplasm);白细胞介素6(Interleukin-6);I类磷脂酰肌醇3-激酶类(Class I Phosphatidylinositol 3-Kinases);细胞系, 肿瘤(Cell Line, Tumor);抗原, CD(Antigens, CD);免疫轭合物(Immunoconjugates);淋巴瘤(Lymphoma);美坦辛(Maytansine);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);抗原, 肿瘤(Antigens, Neoplasm)

DOI 10.1182/bloodadvances.2023012291

PMID 39374583

发布时间 2025-07-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2024年8卷24期

6268-6281页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Blood advances

2024年8卷24期

6268-6281页

检索历史清除

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

检索历史清除